Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Biotech’s Hard Bargain

Investors love drug companies in part because they often have tremendous pricing power. Drugs designed to fight rare diseases routinely cost two or three hundred thousand dollars; cancer drugs often cost a hundred grand. But the signs of a backlash are clear.

Published
10 hours ago
From
The New Yorker
AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. AbbVie plans to submit applications for regulatory approval of its regimen in the European Union in early May.

Published
23 April 2014
From
AbbVie press release
NHS England agrees funding for life-saving hepatitis C drug

NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

Published
17 April 2014
From
NHS England (press release)
England: Patients with end-stage liver disease caused by hepatitis C to get new drug

The NHS is to pay for around 500 people with end-stage liver disease caused by hepatitis C to receive Sofosbuvir, a new drug which could cure them, without waiting for guidance from the advisory body, Nice.

Published
17 April 2014
From
The Guardian
Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

Published
10 April 2014
From
Inter Press Service
Gilead aims to license hepatitis C drug to 3-4 Indian firms

Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

Published
09 April 2014
From
Reuters
Gilead says has discounted hepatitis C drug for some health plans

Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

Published
31 March 2014
From
Reuters
Gilead offers Egypt new hepatitis C drug at 99 percent discount

Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.

Published
24 March 2014
From
Reuters
US Lawmakers Attack Cost of New Hepatitis Drug

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday.

Published
24 March 2014
From
New York Times
Trouble Ahead for Gilead and Sovaldi?

Atop ever-inflating sales estimates for Gilead Science's blockbuster Sovaldi, patent battles also continue to crop up. Late last week Idenix Pharmaceuticals added three more suits to the pile, filing in France, Germany and the UK for patent infringement on nucleosides, a precursor to the compound in Sovaldi. This is in addition to two lawsuits it has pending against Gilead stateside since late last year.

Published
19 March 2014
From
Motley Fool
← First12345...35Next →

Filter by country